On February 3, 2016 MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX), a clinical-stage immuno-oncology drug development company, reported that President and Chief Executive Officer David Hansen is scheduled to present a corporate overview at the 18th Annual BIO CEO & Investor Conference on Tuesday, February 9, 2016, at 10:30 a.m. Eastern time (7:30 a.m. Pacific time) (Press release, MabVax, FEB 3, 2016, View Source [SID:1234508957]). The conference is being held at The Waldorf Astoria New York hotel in New York City.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"This is an exciting time at MabVax with preparations underway to begin Phase I clinical trials with our fully human antibody product HuMab-5B1 as both a therapeutic agent and a new generation PET scan cancer imaging agent," said David Hansen, MabVax’s President and Chief Executive Officer. "We anticipate reporting an interim safety assessment and determination of a maximum tolerated dose in the therapeutics trial and an initial set of disease images in the imaging trial by mid-year 2016. These near-term interim data could provide additional validation for our proprietary approach to immune-oncology. We look forward to updating investors on our progress and upcoming milestones at this well-attended conference."
A live webcast of the presentation will be available on Company’s website at View Source A replay of the presentation will be available for 90 days.